Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
291650
vs
K
KOSPI 200
Over the past 12 months, Aptamer Sciences Inc has underperformed KOSPI 200, delivering a return of +49% compared to KOSPI 200's +50% growth.
Stocks Performance
291650 vs KOSPI 200
Performance Gap
291650 vs KOSPI 200
Performance By Year
291650 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Aptamer Sciences Inc
Glance View
Aptamer Sciences Inc. is a biotechnology company that works with aptamers, which are short DNA or RNA molecules that can bind to specific targets much like antibodies do. The company develops aptamer-based materials and related research tools for use in diagnostics, biosensing, and life science research. It also works on custom aptamer discovery and design for customers that need a molecule to detect or capture a specific target. The company makes money by selling research services, custom development work, and aptamer-related products such as reagents and assay components. Its main customers are pharmaceutical and biotech companies, diagnostic developers, research labs, and other groups that need highly specific molecular binding tools. In some cases, it may also earn revenue from licensing or collaborative development of its aptamer technology. What makes its business different is that it sits at the intersection of drug discovery tools and diagnostics, using aptamers as a programmable alternative to antibodies. That gives it a role as a specialist supplier of target-binding molecules and test components rather than a broad drug maker. Its value comes from helping other companies and labs detect, measure, or capture biological targets more precisely and in a form that is easier to engineer than traditional protein-based binders.